News

Agilent MMR IHC Panel pharmDx (Dako Omnis) Receives FDA Approval as a Companion Diagnostic Test for Colorectal Cancer

Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received FDA approval as a companion diagnostic (CDx) test for colorectal cancer. This test aids in ...
360Dx3d

FDA Approves Agilent CDx Assay for Use With Bristol Myers Squibb Immunotherapies

The MMR IHC Panel PharmaDx (Dako Omnis) is used to identify loss of function in mismatch repair proteins and inform the treatment of colorectal cancer patients.